

SPEAKER AND MODERATOR BIOSKETCHES
WEBINAR 3 - Impact of the Dobbs Decision on Cancer Care:
Ethical, Legal, and Social Implications



Robin Yabroff, PhD, MBA (Co-Moderator)

American Cancer Society

Robin Yabroff, PhD, is an epidemiologist and Scientific Vice President, Health Services Research, at the American Cancer Society. She conducts research on the economic burden of cancer; patterns of cancer care, including high cost prescription drugs; health insurance benefit design; and patient, provider, and health system factors associated with the quality and value of cancer care.

Dr. Yabroff has more than 20 years of health services research experience and currently has adjunct positions within the Department of Medicine, Johns Hopkins University, and the Rollins School of Public Health, Emory University. Prior to joining the American Cancer Society, she held positions within the Office of Health Policy, Assistant Secretary for Planning and Evaluation (ASPE) in the US Department of Health and Human Services, the Health Services and Economics Branch of the National Cancer Institute, and the faculty of the Lombardi Cancer Center, Georgetown University. She earned her PhD in epidemiology from the Johns Hopkins School of Public Health and received an MBA from the University of Rochester.

Dr. Yabroff has co-authored over 300 peer-reviewed journal articles and invited editorials, commentaries, and book chapters. She is a Deputy Editor for the *Journal of the National Cancer Institute*, a founding member of the editorial board of the *Journal of Cancer Survivorship*, and a member of the editorial board of the *JCO Oncology Practice*. Dr. Yabroff has received multiple National Institutes of Health Merit Awards for her research leadership and mentorship.



Nicole Huberfeld, JD (Co-Moderator)

Boston University

Nicole Huberfeld is Edward R. Uteley Professor of Health Law at BU School of Public Health (BUSPH) and Professor of Law at BU School of Law, where she is also Co-Director of the BU Program on Reproductive Justice and affiliate faculty with the Center for Antiracism Research and the Medicaid Policy Lab. Her research studies the intersection of health law and constitutional law, examining law as a determinant of health with research on federalism, Medicaid, health reform, and reproductive care. She is the co-author of two leading health law casebooks and many national and international book chapters, law journal articles, peer-reviewed articles, and commentaries. Her

work has been cited in judicial opinions by the U.S. Supreme Court and other federal and state courts. In 2019, Huberfeld won an Excellence in Teaching Award at BUSPH, and she was nominated for teaching awards in 2021 and 2022 at BU Law. Recently, she became Research

Director for the Uniform Law Commission's Joint Editorial Board on Health Law. Media quotes include the New York Times, NPR, Washington Post, Bloomberg News, Reuters, Huffington Post, Talking Points Memo, National Law Journal, Congressional Quarterly, Politico, and Univision.



I. Glenn Cohen, JD
Harvard University

Prof. Cohen is one of the world's leading experts on the intersection of bioethics (sometimes also called "medical ethics") and the law, as well as health law. He also teaches civil procedure. He has advised the U.S. Vice President on reproductive rights, discussed medical AI policy with members of the Korean Congress, and lectured to legal, medical, and industry conferences around the world.

Prof. Cohen's current projects relate to medical AI, mobile health and other health information technologies, abortion, reproduction/reproductive technology, the therapeutic use of psychedelic drugs, research ethics, organ transplantation, rationing in law and medicine, health policy, FDA law, translational medicine, medical tourism and many other topics. He is the author of more than 200 articles and chapters and is also the author, co-author, editor, or co-editor of more than 18 books.

For his law school teaching he was awarded the HLS Student Government Teaching and Advising Award in 2017. He also sometimes teaches courses at Harvard College and Harvard Medical School. For the public he created the free online Harvard X class Bioethics: The Law, Medicine, and Ethics of Reproductive Technologies and Genetics, which was nominated by Harvard for the Japan Prize.

Prior to becoming a professor, he served as a law clerk to Judge Michael Boudin of the U.S. Court of Appeals for the First Circuit and as a lawyer for U.S. Department of Justice, Civil Division, Appellate Staff, where he handled litigation in the Courts of Appeals and (in conjunction with the Solicitor General's Office) in the U.S. Supreme Court. In his spare time he still litigates, having authored an amicus brief in the U.S. Supreme Court for leading gene scientist Eric Lander in *Association of Molecular Pathology v. Myriad*, concerning whether human genes are patent eligible subject matter, a brief that was extensively discussed by the Justices at oral argument. Most recently he submitted an amicus brief to the U.S. Supreme Court in *Whole Women's Health v. Hellerstedt* (the Texas abortion case, on behalf of himself, Melissa Murray, and B. Jessie Hill). He also provides expert testimony in health law and bioethics litigation.

Cohen was selected as a Radcliffe Institute Fellow for the 2012-2013 year and by the Greenwall Foundation to receive a Faculty Scholar Award in Bioethics. He is also a Fellow at the Hastings Center, the leading bioethics think tank in the United States as well as being a fellow of the Pierre Elliot Trudeau Foundation. He leads the Project on Precision Medicine, Artificial Intelligence, and the Law (PMAIL), which is part of the larger Centre for Advanced Studies in Biomedical Innovation Law (CeBIL). He co-leads the Regulatory Foundations, Ethics, and Law Program of Harvard Catalyst | The Harvard Clinical and Translational Science Center program. He is also the

lead on the Project on Psychedelics Law and Regulation (POPLAR). He previously served as one of the key co-investigators on the multi-million dollar Football Players Health Study at Harvard which is committed to improving the health of NFL players (for more on this work click here). He is also one of three editors-in-chief of the *Journal of Law and the Biosciences*, a peer-reviewed journal published by Oxford University Press, and serves on the editorial board for the *American Journal of Bioethics*. He served on the Steering Committee for Ethics for the Canadian Institutes of Health Research (CIHR), the Canadian counterpart to the NIH, and the Ethics Committee for the American College of Obstetricians and Gynecologists (ACOG). He currently serves on the Ethics Committee of the U.S. Organ Procurement and Transplantation Network (OPTN). He has also served on the bioethics advisory groups for life sciences companies like Otsuka, Illumina, and Bayer.



Lisa Harris, MD, PhD
University of Michigan

Lisa Harris, MD, PhD, is the F. Wallace and Janet Jeffries Professor of Reproductive Health, Professor of Obstetrics and Gynecology, and Professor of Women's and Gender studies at University of Michigan (UM). After college and medical school at Harvard, Dr. Harris completed residency at UC San Francisco, and subsequently was a Robert Wood Johnson Clinical Scholar, and later a Greenwall Faculty Scholar in Bioethics. Because so many issues in reproductive health are tied to history and culture, she subsequently earned a PhD in American Culture. She has included abortion care in her clinical work through her career, in both hospital and outpatient (Planned Parenthood) settings, and founded and

led UM's residency training program in family planning and Fellowship in Complex Family Planning. Her scholarship has made her a national and international thought leader in many arenas, including abortion stigma, conscience and abortion, experiences of abortion care providers, racial stratification of reproduction, and the role of doctors' voices in depolarizing abortion. For the past 18 months she's led UM's post-Roe Task Force, charged with managing the university's preparations after Dobbs. She has served on the Ethics Committee of the American College of Obstetricians and Gynecologists and recently completed six years of service on the Board of Directors of the Society of Family Planning. She serves on the editorial board of the journals *Women's Health Issues* and *Contraception*. Dr. Harris has been an important voice helping the public understand the impact of the Dobbs decision, through numerous media interviews and op ed pieces. She aims to bring nuance and complexity to the issue of abortion, as an antidote to the polarizing terms in which abortion is usually discussed. She has been involved in a range of abortion-related litigation, including serving as a witness in Governor Whitmer's case to prevent Michigan's 1931 abortion ban from coming into effect, and serving as a plaintiff in California's case, *People v. David Daleiden & Sandra Merritt*. She has received a variety of awards for her scholarship and teaching, including the Association of Reproductive Health Professional's Preserving Core Values in Science Award, Outstanding Researcher awards from the Society of Family Planning and from the National Abortion Federation. She was recently appointed Arthur Thurnau Professor, UM's highest award for undergraduate teaching.



Kimberly Mutcherson, JD
Rutgers University

Kimberly Mutcherson is a Professor of Law and former Co-Dean at Rutgers Law School in Camden. She was the first woman, the first Black person, and the first member of the LGBTQ community to be a Dean at Rutgers Law. Professor Mutcherson is a reproductive justice scholar whose work focuses on assisted reproduction and abortion among other topics. Cambridge University Press released her edited volume, *Feminist Judgments: Reproductive Justice Rewritten*, in 2020.

In 2023, Professor Mutcherson received the Trailblazer Award from the New Jersey Women Lawyer's Association. Professor Mutcherson was a co-recipient of the 2021 M. Shanara Gilbert Human Rights Award from the Society of American Law Teachers and the 2020 Association of American Law Schools inaugural Impact Award as one of the creators of the Law Deans Antiracist Clearinghouse Project. Also in 2021, the Rutgers Law School Black Law Students Association honored her with the Dr. Martin Luther King Jr. Champions of Social Justice Award and the Association of Black Women Lawyers of New Jersey celebrated her as a Distinguished Changemaker. Professor Mutcherson received the Center for Reproductive Rights Innovation in Scholarship Award in 2013, a Chancellor's Teaching Excellence Award in 2011, and the Women's Law Caucus Faculty Appreciation Award in 2011 and 2014.

Professor Mutcherson has been a Senior Fellow/Sabbatical Visitor at the Center for Gender and Sexuality Law at Columbia Law School and a Visiting Scholar at the Center for Bioethics at the University of Pennsylvania. She earned her B.A. from the University of Pennsylvania and her J.D. from Columbia Law School. Upon graduation from Columbia, she received the Kirkland and Ellis Fellowship for post-graduate public interest work. Prior to entering academia, Professor Mutcherson was a consulting attorney at the Center for Reproductive Rights and a Staff Attorney at the HIV Law Project.



Lisa A. Schlager

Facing Our Risk of Cancer Empowered (FORCE)

Lisa Schlager is a recognized consumer advocacy leader for people affected by hereditary cancer. As Vice President of Public Policy for FORCE, she spearheads the organization’s legislative and regulatory policy efforts, advocating for the unique needs of the high-risk cancer community.

Well-versed in healthcare and genetic privacy laws—e.g. Genetic Information Nondiscrimination Act (GINA), Women’s Health and Cancer Rights Act (WHCRA), Affordable Care Act—Schlager is the point person on national guidelines and advocacy issues impacting the hereditary cancer community. She possesses expert knowledge on policies affecting individuals at increased risk of cancer, insurance coverage of genetic, screening and preventive services, and targeted treatments for those diagnosed with hereditary cancers.

Ms. Schlager holds leadership positions with a number of cancer and healthcare initiatives in the government, nonprofit, and private sectors. She represents FORCE and the hereditary cancer community as an expert speaker at conferences, events, and in the media.

PLANNING GROUP BIOSKETCHES
WEBINAR SERIES - Impact of the Dobbs Decision on Cancer Care



Karen Basen-Engquist, PhD, MPH (Co-Chair)

The University of Texas MD Anderson Cancer Center

Karen Basen-Engquist, PhD, MPH, is the Annie Laurie Howard Research Distinguished Professor in the Department of Behavioral Science and the Director of the Center for Energy Balance in Cancer Prevention and Survivorship at The University of Texas MD Anderson Cancer Center. Dr. Basen-Engquist's research focuses on cancer survivors and high-risk individuals and investigates the role of health behavior interventions in improving physical functioning, optimizing quality of life, and reducing the risk of cancer, cancer recurrence, and other chronic diseases. In addition, she studies intervention methods for behavior change with a focus on distance-based and mHealth interventions and uses innovative real-time methods for assessing symptoms and behavior in cancer patients and survivors. She currently is the co-chair of LIVES, a national trial of a diet and physical activity intervention for ovarian cancer survivors, and has been a multiple PI and a co-investigator on grants to study the use of wearable and home-based sensors in cancer prevention and survivorship research. Her research on the benefits of physical activity for cancer survivors has been translated into a community program to increase physical activity among minority and medically underserved cancer survivors in Houston, Beaumont, Tyler, and El Paso, Texas, funded by the Cancer Prevention and Research Institute of Texas (CPRIT). Dr. Basen-Engquist's research center is working to expand energy balance research at MD Anderson by facilitating collaboration among investigators with interests in basic science, clinical, and population research related to physical activity, nutrition, obesity, and cancer.

Dr. Basen-Engquist is a member of the National Cancer Policy Forum at the National Academy of Medicine and has served as an organizer of NCPF workshops on incorporating physical activity and weight management programs throughout the cancer continuum, patient navigation, and health literacy. She is the past president of the American Society of Preventive Oncology.



Robin Yabroff, PhD, MBA (Co-Chair)

American Cancer Society

Robin Yabroff, PhD, is an epidemiologist and Scientific Vice President, Health Services Research, at the American Cancer Society. She conducts research on the economic burden of cancer; patterns of cancer care, including high cost prescription drugs; health insurance benefit design; and patient, provider, and health system factors associated with the quality and value of cancer care.

Dr. Yabroff has more than 20 years of health services research experience and currently has adjunct positions within the Department of Medicine, Johns Hopkins University, and the Rollins School of Public Health, Emory University. Prior to joining the American Cancer Society, she held positions within

the Office of Health Policy, Assistant Secretary for Planning and Evaluation (ASPE) in the US Department of Health and Human Services, the Health Services and Economics Branch of the National Cancer Institute, and the faculty of the Lombardi Cancer Center, Georgetown University. She earned her PhD in epidemiology from the Johns Hopkins School of Public Health and received an MBA from the University of Rochester.

Dr. Yabroff has co-authored over 300 peer-reviewed journal articles and invited editorials, commentaries, and book chapters. She is a Deputy Editor for the *Journal of the National Cancer Institute*, a founding member of the editorial board of the *Journal of Cancer Survivorship*, and a member of the editorial board of the *JCO Oncology Practice*. Dr. Yabroff has received multiple National Institutes of Health Merit Awards for her research leadership and mentorship.



Julie Gralow, MD, FACP, FASCO
American Society of Clinical Oncology (ASCO)

Dr. Gralow is the Chief Medical Officer and Executive Vice President of ASCO and brings to her role deep expertise in patient care, research, education, and global health.

Previously, she was the Jill Bennett Endowed Professor of Breast Cancer at the University of Washington School of Medicine, Professor in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, as well as Director of Breast Medical Oncology at the Seattle Cancer Care Alliance.

Dr. Gralow is strongly committed to advancing equity in cancer care. As founder of the Women's Empowerment Cancer Advocacy Network (WE CAN), she supports patient advocates in low- and middle-resource countries. In addition, she served as an adjunct professor in the University of Washington's Department of Global Health, as a member of the University of Washington's Breast Cancer Equity Initiative, as Medical Director for Women's Cancer-related Population Health at the University of Washington, and as an advisory council member for the Uganda Cancer Institute's adult Hematology/Oncology Fellowship Training Program. Dr. Gralow received the ASCO Humanitarian Award in 2018 for her work in empowering women cancer patients and survivors globally.

She is a recognized leader in breast cancer clinical research, and has conducted clinical trials in breast cancer prevention, treatment, and survivorship. Dr. Gralow served in leadership roles for the SWOG Cancer Research Network funded by the National Cancer Institute (NCI), including as Vice Chair of the Breast Cancer Committee and Executive Officer of Breast and Lung Cancer.

Before joining ASCO full-time, Dr. Gralow served the Society in a variety of volunteer and leadership roles, including chairing the ASCO Academic Global Oncology Task Force, co-chairing the ASCO Resource Stratified Guideline Advisory Group, and serving on the editorial board of the European Society of Medical Oncology (ESMO)/ASCO Global Curriculum in Medical Oncology.

She also has been involved with numerous other nonprofit organizations, including Team Survivor Northwest, an exercise and fitness program for woman cancer survivors which she co-founded in 1995 and serves as Team Physician; a medical advisory committee member for Cierra

Sisters African American Support Group; an advisory board member of Global Focus on Cancer; and a Board member of Peace Island Medical Center, a rural access hospital in Washington State.

Dr. Gralow received her bachelor's degree from Stanford University and her medical degree from the University of Southern California School of Medicine. She trained in internal medicine at Brigham and Women's Hospital at Harvard Medical School and completed a medical oncology fellowship at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle.



Roy S. Herbst, MD, PhD

Yale Comprehensive Cancer Center, Yale School of Medicine, and Smilow Cancer Hospital

Roy S. Herbst, MD, PhD, is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, CT.

Dr. Herbst has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib, atezolizumab, and pembrolizumab), which have revolutionized the field and greatly enhanced patient survival. His leadership in targeted therapeutics resulted in a 2020 ASCO plenary talk and publication of results of the third-generation EGFR-inhibitor osimertinib for the treatment of resected EGFR-mutant NSCLC in the *New England Journal of Medicine*. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. In 2015 and again in 2020, his team at Yale was awarded a Lung Cancer SPORE (P50 grant) by the NCI, which has identified new immunotherapies and mechanisms of sensitivity and resistance to EGFR targeted therapies.

His work on "umbrella" trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. Nationally, he works closely with public-private partnerships to develop large master protocol clinical studies, such as Lung-MAP. He testified on the subject of modernizing clinical trials during the 21st Century Cures hearing before the US House of Representatives Subcommittee on Health and has served as a prominent figure in the public policy arena, for nine years having served as a member of the National Academy of Medicine's Cancer Policy Forum, for which he organized several meetings focused on policy issues in personalized medicine and tobacco control.

Dr. Herbst is a highly respected clinician- scientist who has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer. He has authored or co-authored more than 350 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the *Journal of Clinical Oncology*, *Clinical Cancer Research*, *Lancet*, and the *New England Journal of Medicine*. Work published in *Nature* was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.

He is a Fellow of the American Society of Clinical Oncology and a member of the American Association of Cancer Research (AACR), where he serves as an elected member of its board of directors and chairs the Tobacco Task Force. He has been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings. In 2019 he was elected to the International Association for the Study of Lung Cancer (IASLC) board of directors. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice chair of the Southwestern Oncology Group's (SWOG) Lung Committee.

For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the IASLC at their 17th World Conference on Lung Cancer in Vienna, Austria. A team of Yale Cancer Center investigators led by Roy S. Herbst, MD, PhD, was awarded the 2018 Team Science Award from the Association for Clinical and Translational Science (ACTS) for its pioneering work in advancing our understanding of Immunotherapy. In 2020, Dr. Herbst was awarded the AACR Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy.



Nicole Huberfeld, JD
Boston University

Nicole Huberfeld is Edward R. Uteley Professor of Health Law at BU School of Public Health (BUSPH) and Professor of Law at BU School of Law, where she is also Co-Director of the BU Program on Reproductive Justice and affiliate faculty with the Center for Antiracism Research and the Medicaid Policy Lab. Her research studies the intersection of health law and constitutional law, examining law as a determinant of health with research on federalism, Medicaid, health reform, and reproductive care. She is the co-author of two leading health law casebooks and many national and international book chapters, law journal articles, peer-reviewed articles, and commentaries. Her

work has been cited in judicial opinions by the U.S. Supreme Court and other federal and state courts. In 2019, Huberfeld won an Excellence in Teaching Award at BUSPH, and she was nominated for teaching awards in 2021 and 2022 at BU Law. Recently, she became Research Director for the Uniform Law Commission's Joint Editorial Board on Health Law. Media quotes include the New York Times, NPR, Washington Post, Bloomberg News, Reuters, Huffington Post, Talking Points Memo, National Law Journal, Congressional Quarterly, Politico, and Univision.



Beth Y. Karlan, MD

University of California, Los Angeles, Jonsson Comprehensive Cancer Center

Beth Y. Karlan, MD, is Professor and Vice Chair of Women's Health Research in the Department of Obstetrics and Gynecology at the David Geffen School of Medicine, University of California Los Angeles (UCLA). She is also the Director of Cancer Population Genetics at the UCLA-Jonsson Comprehensive Cancer Center. Dr. Karlan's research focuses on ovarian and other women's cancers as well as inherited cancer susceptibility. She has authored over 400 peer-reviewed research publications and for over ten years served as Editor-in-Chief of the scientific journals *Gynecologic Oncology* and *Gynecologic Oncology Reports*. She is an American Cancer Society Clinical Research Professor, has served in many national

leadership roles including president of the Society of Gynecologic Oncology, and has helped train a generation of physicians and scientists. In 2012, Dr. Karlan was appointed by the Obama White House to serve on the National Cancer Advisory Board and in 2015 she was elected to membership in the National Academy of Medicine. Dr. Karlan is a Fellow of the American Society of Clinical Oncology and a member of the National Cancer Policy Forum. Her contributions have been recognized by her peers with multiple awards including a Lifetime Achievement Award from the International Society of Gynecologic Cancer.



Alexander Melamed, MD

Massachusetts General Hospital

Alexander Melamed is an Assistant Professor in the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology at New York-Presbyterian/ Columbia University Medical Center. He provides medical and surgical care to women with cancers of the reproductive system including ovarian, uterine, cervical, and vulvar cancer. His research focuses on improving outcomes among people with cancer and promoting the use of robust analytical methods for observational studies in oncology. Dr. Melamed's work has helped to define the role of minimally invasive surgery in gynecologic oncology and identified strategies that reduce unnecessary side effects in the treatment of ovarian cancer, and contributed to a shift in the international standard of care for the treatment of early-stage

cervical cancer. Dr. Melamed is the recipient of career development awards from the National Institute of Health's National Center for Advancing Translational Science, the American Society of Clinical Oncology's Conquer Cancer Foundation, and the Department of Defense's Ovarian Cancer Research Program.



Kayte Spector-Bagdady, JD, MBioethics
University of Michigan

Kayte Spector-Bagdady, JD, MBioethics is an Assistant Professor of Obstetrics and Gynecology and interim Co-Director at the Center for Bioethics and Social Sciences in Medicine and at the University of Michigan Medical School. She is also the Chair of the U-M Research Ethics Committee, the ethicist on the Human Data and Biospecimen Release Committee, and a clinical ethicist. She teaches the Responsible Conduct of Research as well as Research Ethics and the Law and is an Associate Editor of the American Journal of Bioethics.

The overarching goal of Prof. Spector's work is improving the governance of secondary research with health data and specimens to increase the accessibility of data and generalizability of advances across diverse communities.

She is the PI of a National Human Genome Research Institute KO1 studying how and why geneticists select datasets for their research and a National Center for Advancing Translational Sciences RO1 on hospitals sharing patient data with commercial entities. Her recent articles have been published in The New England Journal of Medicine, Science, JAMA, and Nature Medicine, and her research or expertise has appeared in the NY Times, The Washington Post, The Wall Street Journal, TIME, and CNN.

Professor Spector was an Associate Director for President Obama's Presidential Commission for the Study of Bioethical Issues, and is a former Board Member of the American Society for Bioethics & Humanities and practicing FDA law attorney. She graduated from the University of Pennsylvania Law School and School of Medicine after attending Middlebury College.